​

Teva Pharmaceutical Industries (TEVA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TEVA Stock Forecast

Teva Pharmaceutical Industries stock forecast is as follows: an average price target of $24.20 (represents a 9.80% upside from TEVA’s last price of $22.04) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

TEVA Price Target

The average price target for Teva Pharmaceutical Industries (TEVA) is $24.20 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $20.00. This represents a potential 9.80% upside from TEVA's last price of $22.04.

TEVA Analyst Ratings

Buy

According to 8 Wall Street analysts, Teva Pharmaceutical Industries's rating consensus is 'Buy'. The analyst rating breakdown for TEVA stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 1 'Hold' (12.50%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).

Teva Pharmaceutical Industries Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 18, 2024Ashwani VermaUBS$28.00$21.2032.08%27.04%
Dec 18, 2024Balaji PrasadBarclays$28.00$21.2032.08%27.04%
Oct 23, 2024Balaji PrasadBarclays$25.00$18.3836.02%13.43%
Oct 01, 2024Jason GerberryBank of America Securities$22.00$17.7523.94%-0.18%
Sep 03, 2024Ashwani VermaUBS$26.00$18.4341.11%17.97%
Aug 28, 2024David AmsellemPiper Sandler$23.00$18.6123.56%4.36%
Aug 01, 2024Balaji PrasadBarclays$22.00$17.4326.22%-0.18%
Jul 10, 2024Jasper HellwegArgus Research$20.00$15.8126.50%-9.26%
Jul 10, 2024Ashwani VermaUBS$24.00$15.8151.80%8.89%
Jun 05, 2024Balaji PrasadBarclays$21.00$16.6326.28%-4.72%
May 23, 2024Balaji PrasadBarclays$20.00$16.7619.33%-9.26%
May 13, 2024David AmsellemPiper Sandler$20.00$16.8918.38%-9.26%
Feb 12, 2024David AmsellemPiper Sandler$19.00$12.0158.20%-13.79%
Jan 23, 2024Glen SantangeloJefferies$14.00$11.9916.76%-36.48%
Nov 14, 2022J.P. Morgan$10.00$9.485.49%-54.63%
Jun 13, 2022Ashwani VermaUBS$10.00$7.8926.74%-54.63%
May 04, 2022Piper Sandler$7.00$8.60-18.60%-68.24%
Apr 20, 2022Balaji PrasadBarclays$13.00$9.7932.79%-41.02%

The latest Teva Pharmaceutical Industries stock forecast, released on Dec 18, 2024 by Ashwani Verma from UBS, set a price target of $28.00, which represents a 32.08% increase from the stock price at the time of the forecast ($21.20), and a 27.04% increase from TEVA last price ($22.04).

Teva Pharmaceutical Industries Price Target by Period

1M3M12M
# Anlaysts2314
Avg Price Target$28.00$27.00$22.29
Last Closing Price$22.04$22.04$22.04
Upside/Downside27.04%22.50%1.13%

In the current month, the average price target of Teva Pharmaceutical Industries stock is $28.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 27.04% increase as opposed to Teva Pharmaceutical Industries's last price of $22.04. This month's average price target is up 3.70% compared to last quarter, and up 25.62% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 18, 2024UBSBuyBuyHold
Dec 18, 2024BarclaysOverweightOverweightHold
Dec 03, 2024Bank of America SecuritiesBuyBuyHold
Oct 23, 2024BarclaysOverweightOverweightHold
Oct 01, 2024Bank of America SecuritiesBuyBuyHold
Sep 09, 2024JefferiesBuyBuyHold
Sep 03, 2024UBSBuyBuyHold
Aug 28, 2024Piper SandlerOverweightOverweightHold
Aug 01, 2024BarclaysOverweightOverweightHold
Jul 10, 2024UBSBuyBuyHold
Jun 27, 2024JefferiesBuyBuyHold
Jun 13, 2024Piper SandlerOverweightOverweightHold
Jun 05, 2024BarclaysOverweightOverweightHold
May 13, 2024Piper SandlerOverweightOverweightHold
May 09, 2024Bank of America SecuritiesBuyBuyHold
May 09, 2024BarclaysOverweightOverweightHold
Feb 12, 2024Piper SandlerUnderweightOverweightUpgrade
Jan 23, 2024JefferiesPositiveBuyUpgrade
Nov 27, 2023UBSNeutralBuyUpgrade
May 18, 2023Evercore ISIOutperformUpgrade
Jan 26, 2023JefferiesPositiveDowngrade
Nov 23, 2022Piper SandlerUnderweightUnderweightHold
Nov 14, 2022Goldman SachsUnderweightDowngrade
Aug 05, 2022Bank of America SecuritiesNeutralBuyUpgrade
Jun 13, 2022UBSNeutralInitialise
May 17, 2022Bank of America SecuritiesNeutralUpgrade
Apr 26, 2022Zacks Investment ResearchHoldUpgrade
Feb 18, 2022BarclaysEqual-WeightEqual-WeightHold

Teva Pharmaceutical Industries's last stock rating was published by UBS on Dec 18, 2024. The company gave TEVA a "Buy" rating, the same as its previous rate.

Teva Pharmaceutical Industries Financial Forecast

Teva Pharmaceutical Industries Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$4.46B$3.85B$3.88B$3.66B$3.88B$3.60B$3.79B$3.66B$4.10B$3.89B$3.91B$3.98B$4.45B$3.98B$3.87B$4.36B$3.99B$4.26B$4.34B$4.29B$5.07B$5.63B
Avg Forecast$4.29B$4.47B$4.26B$3.94B$4.13B$4.14B$4.06B$3.73B$4.03B$3.73B$3.71B$3.62B$3.89B$3.84B$3.78B$3.74B$4.28B$4.03B$4.02B$4.02B$4.37B$4.07B$3.93B$4.15B$4.35B$4.24B$4.25B$4.38B$3.61B$5.47B
High Forecast$4.31B$4.49B$4.28B$3.99B$4.20B$4.14B$4.06B$3.73B$4.08B$3.81B$3.73B$3.64B$3.96B$3.84B$3.78B$3.74B$4.28B$4.03B$4.02B$4.02B$4.37B$4.07B$3.93B$4.15B$4.35B$4.24B$4.25B$4.38B$4.33B$6.56B
Low Forecast$4.27B$4.45B$4.24B$3.91B$4.08B$4.14B$4.06B$3.73B$3.93B$3.59B$3.70B$3.61B$3.83B$3.84B$3.78B$3.74B$4.28B$4.03B$4.02B$4.02B$4.37B$4.07B$3.93B$4.15B$4.35B$4.24B$4.25B$4.38B$2.89B$4.37B
# Analysts11115433685443435454516811711771720
Surprise %--------1.11%1.03%1.04%1.01%1.00%0.94%1.00%0.98%0.96%0.96%0.97%0.99%1.02%0.98%0.98%1.05%0.92%1.01%1.02%0.98%1.40%1.03%

Teva Pharmaceutical Industries's average Quarter revenue forecast for Mar 24 based on 3 analysts is $3.73B, with a low forecast of $3.73B, and a high forecast of $3.73B. TEVA's average Quarter revenue forecast represents a -16.27% decrease compared to the company's last Quarter revenue of $4.46B (Dec 23).

Teva Pharmaceutical Industries EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11115433685443435454516811711771720
EBITDA--------$755.00M$1.04B$979.00M$813.00M$1.05B$993.00M$1.05B$1.01B$1.09B$1.04B$1.09B$1.13B$1.12B$1.08B$1.07B$1.33B$1.12B$1.11B$1.13B$1.08B$1.62B$1.63B
Avg Forecast$230.20M$239.69M$228.38M$211.62M$221.67M$222.07M$217.55M$390.83M$216.01M$200.24M$199.26M$355.30M$231.28M$995.73M$978.91M$323.00M$1.11B$1.04B$1.04B$750.42M$1.13B$1.06B$1.02B$450.61M$1.13B$1.10B$1.10B$545.52M$1.28B$1.35B
High Forecast$231.41M$240.95M$229.58M$213.85M$225.46M$222.29M$217.55M$469.00M$218.74M$204.49M$200.31M$426.36M$277.54M$995.73M$978.91M$387.60M$1.11B$1.04B$1.04B$900.51M$1.13B$1.06B$1.02B$540.73M$1.13B$1.10B$1.10B$654.62M$1.53B$1.61B
Low Forecast$229.30M$238.74M$227.48M$209.94M$218.97M$221.85M$217.55M$312.66M$210.57M$192.35M$198.48M$284.24M$185.03M$995.73M$978.91M$258.40M$1.11B$1.04B$1.04B$600.34M$1.13B$1.06B$1.02B$360.49M$1.13B$1.10B$1.10B$436.41M$1.02B$1.08B
Surprise %--------3.50%5.22%4.91%2.29%4.54%1.00%1.07%3.13%0.98%0.99%1.04%1.51%0.98%1.03%1.05%2.96%0.99%1.01%1.02%1.99%1.27%1.21%

3 analysts predict TEVA's average Quarter EBITDA for Mar 24 to be $390.83M, with a high of $469.00M and a low of $312.66M. This is -48.23% lower than Teva Pharmaceutical Industries's previous annual EBITDA (Dec 23) of $755.00M.

Teva Pharmaceutical Industries Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11115433685443435454516811711771720
Net Income--------$461.00M$80.00M$-863.00M$-239.00M$-1.25B$56.00M$-260.00M$-973.00M$-151.00M$292.00M$207.00M$77.00M$150.00M$-4.47B$140.00M$69.00M$80.00M$-303.00M$-671.00M$-105.00M$1.12B$645.00M
Avg Forecast$853.52M$843.33M$745.29M$605.82M$794.62M$749.20M$625.42M$582.14M$869.59M$688.69M$595.09M$631.10M$-164.91M$697.77M$658.68M$622.19M$831.43M$730.32M$671.12M$71.78M$711.83M$659.54M$595.65M$49.12M$686.82M$670.76M$647.75M$-101.38M$735.52M$626.21M
High Forecast$859.35M$849.08M$750.37M$617.69M$885.43M$752.18M$629.69M$582.25M$985.53M$767.72M$599.14M$635.41M$-131.92M$697.77M$658.68M$622.19M$831.43M$730.32M$671.12M$86.14M$711.83M$659.54M$595.65M$58.94M$686.82M$670.76M$647.75M$-81.10M$882.63M$751.46M
Low Forecast$849.15M$839.01M$741.47M$593.94M$749.21M$746.22M$622.21M$582.02M$834.81M$632.25M$592.04M$627.87M$-197.89M$697.77M$658.68M$622.19M$831.43M$730.32M$671.12M$57.42M$711.83M$659.54M$595.65M$39.29M$686.82M$670.76M$647.75M$-121.66M$588.42M$500.97M
Surprise %--------0.53%0.12%-1.45%-0.38%7.60%0.08%-0.39%-1.56%-0.18%0.40%0.31%1.07%0.21%-6.79%0.24%1.40%0.12%-0.45%-1.04%1.04%1.52%1.03%

Teva Pharmaceutical Industries's average Quarter net income forecast for Mar 24 is $582.14M, with a range of $582.02M to $582.25M. TEVA's average Quarter net income forecast represents a 26.28% increase compared to the company's last Quarter net income of $461.00M (Dec 23).

Teva Pharmaceutical Industries SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11115433685443435454516811711771720
SG&A--------$901.00M$844.00M$910.00M$842.00M$838.00M$822.00M$907.00M$880.00M$908.00M$888.00M$857.00M$875.00M$1.01B$884.00M$861.00M$917.00M$1.02B$880.00M$962.00M$940.00M$1.10B$1.21B
Avg Forecast$960.80M$1.00B$953.18M$883.23M$925.19M$926.87M$907.97M$835.53M$901.58M$835.75M$831.66M$810.43M$941.73M$859.81M$845.28M$836.90M$958.55M$902.00M$899.54M$815.68M$978.68M$911.50M$880.37M$652.78M$974.25M$948.27M$950.92M$907.59M$722.39M$1.17B
High Forecast$965.84M$1.01B$958.18M$892.55M$940.98M$927.78M$907.97M$835.53M$912.93M$853.46M$836.02M$814.68M$1.13B$859.81M$845.28M$836.90M$958.55M$902.00M$899.54M$978.81M$978.68M$911.50M$880.37M$783.34M$974.25M$948.27M$950.92M$1.09B$866.87M$1.41B
Low Forecast$957.01M$996.44M$949.42M$876.23M$913.90M$925.95M$907.97M$835.53M$878.87M$802.79M$828.38M$807.24M$753.38M$859.81M$845.28M$836.90M$958.55M$902.00M$899.54M$652.54M$978.68M$911.50M$880.37M$522.22M$974.25M$948.27M$950.92M$726.07M$577.91M$937.48M
Surprise %--------1.00%1.01%1.09%1.04%0.89%0.96%1.07%1.05%0.95%0.98%0.95%1.07%1.03%0.97%0.98%1.40%1.05%0.93%1.01%1.04%1.52%1.03%

Teva Pharmaceutical Industries's average Quarter SG&A projection for Mar 24 is $835.53M, based on 3 Wall Street analysts, with a range of $835.53M to $835.53M. The forecast indicates a -7.27% fall compared to TEVA last annual SG&A of $901.00M (Dec 23).

Teva Pharmaceutical Industries EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11115433685443435454516811711771720
EPS--------$0.41$0.07$-0.77$-0.21$-1.13$0.05$-0.23$-0.88$-0.14$0.26$0.19$0.07$0.14$-4.08$0.13$0.06$0.07$-0.28$-0.61$-0.09$1.04$0.57
Avg Forecast$0.75$0.74$0.66$0.53$0.70$0.66$0.55$0.51$0.77$0.61$0.53$0.56$0.72$0.62$0.58$0.55$0.73$0.64$0.59$0.59$0.63$0.58$0.53$0.59$0.61$0.59$0.57$0.58$0.44$1.00
High Forecast$0.76$0.75$0.66$0.55$0.78$0.66$0.56$0.51$0.87$0.68$0.53$0.56$0.73$0.62$0.58$0.55$0.73$0.64$0.59$0.59$0.63$0.58$0.53$0.59$0.61$0.59$0.57$0.58$0.53$1.20
Low Forecast$0.75$0.74$0.65$0.52$0.66$0.66$0.55$0.51$0.74$0.56$0.52$0.55$0.70$0.62$0.58$0.55$0.73$0.64$0.59$0.59$0.63$0.58$0.53$0.59$0.61$0.59$0.57$0.58$0.35$0.80
Surprise %--------0.53%0.12%-1.47%-0.38%-1.58%0.08%-0.40%-1.60%-0.19%0.40%0.32%0.12%0.22%-7.01%0.25%0.10%0.12%-0.47%-1.07%-0.15%2.36%0.57%

According to 3 Wall Street analysts, Teva Pharmaceutical Industries's projected average Quarter EPS for Mar 24 is $0.51, with a low estimate of $0.51 and a high estimate of $0.51. This represents a 25.32% increase compared to TEVA previous annual EPS of $0.41 (Dec 23).

Teva Pharmaceutical Industries Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CGCCanopy Growth$2.74$14.47428.10%Hold
SNDLSNDL$1.79$3.2581.56%Hold
TLRYTilray Brands$1.33$2.2569.17%Hold
ELANElanco Animal Health$12.11$18.0048.64%Buy
ACBAurora Cannabis$4.25$5.9239.29%Hold
ZTSZoetis$162.93$221.0035.64%Buy
VTRSViatris$12.45$15.0020.48%Hold
CRONCronos Group$2.02$2.3013.86%Hold
TEVATeva Pharmaceutical Industries$22.04$24.209.80%Buy
BHCBausch Health Companies$8.06$8.333.35%Hold
HLNHaleon$9.54$9.15-4.09%Buy
LFCRLifecore Biomedical$7.43$6.50-12.52%Buy

TEVA Forecast FAQ

Is Teva Pharmaceutical Industries a good buy?

Yes, according to 8 Wall Street analysts, Teva Pharmaceutical Industries (TEVA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of TEVA's total ratings.

What is TEVA's price target?

Teva Pharmaceutical Industries (TEVA) average price target is $24.2 with a range of $20 to $28, implying a 9.80% from its last price of $22.04. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Teva Pharmaceutical Industries stock go up soon?

According to Wall Street analysts' prediction for TEVA stock, the company can go up by 9.80% (from the last price of $22.04 to the average price target of $24.2), up by 27.04% based on the highest stock price target, and down by -9.26% based on the lowest stock price target.

Can Teva Pharmaceutical Industries stock reach $30?

TEVA's average twelve months analyst stock price target of $24.2 does not support the claim that Teva Pharmaceutical Industries can reach $30 in the near future.

What is Teva Pharmaceutical Industries's current price target trend?

2 Wall Street analysts forecast a $28 price target for Teva Pharmaceutical Industries (TEVA) this month, up 27.04% from its last price of $22.04. Compared to the last 3 and 12 months, the average price target increased by 22.50% and increased by 1.13%, respectively.

What are Teva Pharmaceutical Industries's analysts' financial forecasts?

Teva Pharmaceutical Industries's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $16.06B (high $16.13B, low $16B), average EBITDA is $1.05B (high $1.13B, low $971.03M), average net income is $2.75B (high $2.85B, low $2.7B), average SG&A $3.6B (high $3.61B, low $3.58B), and average EPS is $2.43 (high $2.52, low $2.38). TEVA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $16.96B (high $17.07B, low $16.88B), average EBITDA is $909.88M (high $915.78M, low $905.46M), average net income is $3.05B (high $3.08B, low $3.02B), average SG&A $3.8B (high $3.82B, low $3.78B), and average EPS is $2.69 (high $2.72, low $2.67).

Did the TEVA's actual financial results beat the analysts' financial forecasts?

Based on Teva Pharmaceutical Industries's last annual report (Dec 2023), the company's revenue was $15.85B, beating the average analysts forecast of $15.09B by 4.99%. Apple's EBITDA was $433M, missing the average prediction of $970.82M by -55.40%. The company's net income was $-559M, missing the average estimation of $2.78B by -120.08%. Apple's SG&A was $3.5B, beating the average forecast of $3.38B by 3.51%. Lastly, the company's EPS was $-0.5, missing the average prediction of $2.46 by -120.34%. In terms of the last quarterly report (Dec 2023), Teva Pharmaceutical Industries's revenue was $4.46B, beating the average analysts' forecast of $4.03B by 10.69%. The company's EBITDA was $755M, beating the average prediction of $216.01M by 249.51%. Teva Pharmaceutical Industries's net income was $461M, missing the average estimation of $869.59M by -46.99%. The company's SG&A was $901M, missing the average forecast of $901.58M by -0.06%. Lastly, the company's EPS was $0.41, missing the average prediction of $0.768 by -46.58%